Company Overview
About Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company founded in 2019 with a mission to develop off-the-shelf, allogeneic natural killer (NK) cell therapies that can transform cancer treatment. NK cells are innate immune cells that can identify and kill cancer cells without requiring the patient-specific manufacturing that makes autologous CAR-T therapies so expensive and logistically complex. Artiva's allogeneic (donor-derived) approach enables manufacturing at scale from healthy donors, producing standardized cell therapy products that can be stored and shipped like conventional drugs.
Business Model & Competitive Advantage
Artiva completed its Nasdaq IPO in June 2024 under ticker symbol ARTV, following a Series C financing round of $150M. Total private funding prior to IPO exceeded $230M, from investors including GV (Google Ventures), Novo Holdings, Leaps by Bayer, and Foresite Capital. The company's lead program, AB-101, is an unmodified allogeneic NK cell therapy being evaluated in B-cell malignancies (blood cancers) and autoimmune diseases — including a clinical collaboration with Genentech targeting lupus. Artiva also has a CAR-NK platform (AB-201 and others) that adds chimeric antigen receptors to NK cells for enhanced tumor targeting.
Competitive Landscape 2025–2026
The NK cell therapy field has attracted significant investment as an alternative to CAR-T therapies, which require individualized manufacturing (4-6 weeks per patient) at costs exceeding $400K per treatment. Artiva's off-the-shelf model targets a much lower cost of goods and faster time to treatment, which is particularly important for hematologic malignancies where disease can progress rapidly. Competitor programs from Fate Therapeutics (acquired by Nkarta), Nkarta, and Cytovia are pursuing similar NK approaches, with Artiva distinguished by its autoimmune disease expansion strategy.
Key Differentiators
Emerging Innovator
Artiva Biotherapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare Artiva Biotherapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Artiva Biotherapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Artiva Biotherapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Artiva Biotherapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →